GlassScriptPhysician profile
Jennifer Squires
NPI 1306880588
$1,245.53
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $286 · 2024: $488 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $171.28 | 2023-2024 | Rybrevant, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $128.37 | 2023-2025 | Iclusig |
| Abbvie INC. | $83.26 | 2024 | |
| Iovance Biotherapeutics, INC. | $65.60 | 2024-2025 | Amtagvi |
| Beigene USA, INC. | $64.43 | 2023-2024 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $59.57 | 2024-2025 | |
| Coherus Oncology, INC. | $54.81 | 2025 | Udenyca, Loqtorzi |
| Incyte Corporation | $49.25 | 2024-2025 | Jakafi, Jakafi |
| Array Biopharma INC | $49.21 | 2024 | Braftovi, Mektovi, Tukysa |
| Genzyme Corporation | $47.90 | 2024-2025 | |
| Sobi, INC | $40.13 | 2024 | |
| Glaxosmithkline, LLC. | $38.42 | 2025 | Zejula, Jemperli, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $38.30 | 2024 | Libtayo |
| Syndax Pharmaceuticals, INC. | $33.70 | 2025 | |
| Mirati Therapeutics, INC. | $32.72 | 2023 | Krazati |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $31.82 | 2024 | Besremi |
| Pfizer INC. | $29.59 | 2025 | |
| Emd Serono, INC. | $27.44 | 2024 | |
| Taiho Oncology, INC. | $26.35 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.22 | 2025 | Lynparza |
| Exelixis INC. | $25.84 | 2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $24.15 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.86 | 2025 | |
| Daiichi Sankyo INC. | $21.35 | 2025 | Injectafer |
| Sun Pharmaceutical Industries INC. | $19.90 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18.16 | 2025 | Qinlock, Romvimza |
| Puma Biotechnology, INC. | $15.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.